FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease
Por:
Garcia-Recio S, Thennavan A, East M, Parker J, Cejalvo J, Garay J, Hollern D, He X, Mott K, Galvan P, Fan C, Selitsky S, Coffey A, Marron D, Braso-Maristany F, Burgues O, Albanell J, Rojo F, Lluch A, de Duenas E, Rosen J, Johnson G, Carey L, Prat A, Perou C
Publicada:
1 sep 2020
Resumen:
Mechanisms driving tumor progression from less aggressive subtypes to more aggressive states represent key targets for therapy. We identified a subset of luminal A primary breast tumors that give rise to HER2-enriched (HER2E) subtype metastases, but remain clinically HER2 negative (cHER2). By testing the unique genetic and transcriptomic features of these cases, we developed the hypothesis that FGFR4 likely participates in this subtype switching. To evaluate this, we developed 2 FGFR4 genomic signatures using a patient-derived xenograft (PDX) model treated with an FGFR4 inhibitor, which inhibited PDX growth in vivo. Bulk tumor gene expression analysis and single-cell RNA sequencing demonstrated that the inhibition of FGFR4 signaling caused molecular switching. In the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) breast cancer cohort, FGFR4-induced and FGFR4-repressed signatures each predicted overall survival. Additionally, the FGFR4-induced signature was an independent prognostic factor beyond subtype and stage. Supervised analysis of 77 primary tumors with paired metastases revealed that the FGFR4-induced signature was significantly higher in luminal/ER . tumor metastases compared with their primaries. Finally, multivariate analysis demonstrated that the FGFR4-induced signature also predicted site-specific metastasis for lung, liver, and brain, but not for bone or lymph nodes. These data identify a link between FGFR4-regulated genes and metastasis, suggesting treatment options for FGFR4-positive patients, whose high expression is not caused by mutation or amplification.
Filiaciones:
Garcia-Recio S:
Univ N Carolina, Lineberger Comprehens Ctr, Chapel Hill, NC 27599 USA
Univ N Carolina, Dept Genet, Sch Med, Chapel Hill, NC 27599 USA
Thennavan A:
Univ N Carolina, Lineberger Comprehens Ctr, Chapel Hill, NC 27599 USA
Univ N Carolina, Sch Dent, Oral & Craniofacial Biomed Program, Chapel Hill, NC 27599 USA
East M:
Univ N Carolina, Sch Med, Dept Pharmacol, Dept Med, Chapel Hill, NC 27599 USA
Parker J:
Univ N Carolina, Lineberger Comprehens Ctr, Chapel Hill, NC 27599 USA
Univ N Carolina, Dept Genet, Sch Med, Chapel Hill, NC 27599 USA
Cejalvo J:
Translat Genom & Targeted Therapeut Oncol IDIBAPS, Barcelona, Spain
Hosp Clin Barcelona, Med Oncol Dept, Barcelona, Spain
Garay J:
Univ N Carolina, Lineberger Comprehens Ctr, Chapel Hill, NC 27599 USA
Univ N Carolina, Dept Genet, Sch Med, Chapel Hill, NC 27599 USA
Hollern D:
Univ N Carolina, Lineberger Comprehens Ctr, Chapel Hill, NC 27599 USA
Univ N Carolina, Dept Genet, Sch Med, Chapel Hill, NC 27599 USA
He X:
Univ N Carolina, Lineberger Comprehens Ctr, Chapel Hill, NC 27599 USA
Univ N Carolina, Dept Genet, Sch Med, Chapel Hill, NC 27599 USA
Mott K:
Univ N Carolina, Lineberger Comprehens Ctr, Chapel Hill, NC 27599 USA
Univ N Carolina, Dept Genet, Sch Med, Chapel Hill, NC 27599 USA
Galvan P:
Translat Genom & Targeted Therapeut Oncol IDIBAPS, Barcelona, Spain
Hosp Clin Barcelona, Med Oncol Dept, Barcelona, Spain
Fan C:
Univ N Carolina, Lineberger Comprehens Ctr, Chapel Hill, NC 27599 USA
Univ N Carolina, Dept Genet, Sch Med, Chapel Hill, NC 27599 USA
Selitsky S:
Univ N Carolina, Lineberger Comprehens Ctr, Chapel Hill, NC 27599 USA
Coffey A:
Univ N Carolina, Lineberger Comprehens Ctr, Chapel Hill, NC 27599 USA
Marron D:
Univ N Carolina, Lineberger Comprehens Ctr, Chapel Hill, NC 27599 USA
Braso-Maristany F:
Translat Genom & Targeted Therapeut Oncol IDIBAPS, Barcelona, Spain
Hosp Clin Barcelona, Med Oncol Dept, Barcelona, Spain
Burgues O:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Hosp Clin Univ Valencia, Dept Pathol, Valencia, Spain
Albanell J:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Ctr Invest Biomed Red Oncol CIBERONC ISCIII, Madrid, Spain
IMIM Hosp del Mar Med Res Inst, Barcelona, Spain
Hosp del Mar, Med Oncol Dept, Barcelona, Spain
Univ Pompeu Fabra, Barcelona, Spain
Rojo F:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Ctr Invest Biomed Red Oncol CIBERONC ISCIII, Madrid, Spain
Fdn Jimenez Diaz, Madrid, Spain
Lluch A:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Ctr Invest Biomed Red Oncol CIBERONC ISCIII, Madrid, Spain
Hosp Clin Univ Valencia, Valencia, Spain
Univ Valencia, Biomed Res Inst Incl, Valencia, Spain
de Duenas E:
Spanish Breast Canc Grp, GEICAM, Madrid, Spain
Ctr Invest Biomed Red Oncol CIBERONC ISCIII, Madrid, Spain
Hosp Prov Castellon, Castellon de La Plana, Spain
Rosen J:
Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX USA
Johnson G:
Univ N Carolina, Sch Med, Dept Pharmacol, Dept Med, Chapel Hill, NC 27599 USA
Carey L:
Univ N Carolina, Sch Med, Dept Med, Div Hematol Oncol, Chapel Hill, NC 27599 USA
Prat A:
Translat Genom & Targeted Therapeut Oncol IDIBAPS, Barcelona, Spain
Hosp Clin Barcelona, Med Oncol Dept, Barcelona, Spain
SOLTI Breast Canc Res Grp, Barcelona, Spain
Perou C:
Univ N Carolina, Lineberger Comprehens Ctr, Chapel Hill, NC 27599 USA
Univ N Carolina, Dept Genet, Sch Med, Chapel Hill, NC 27599 USA
Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA
|